MHRA approval was for ADVENT not NWBO. The Advent facility had only been approved for producing cell-therapies for clinical trials/compassionate use, NOT for commercial products. MHRA approved Advent as a commerical production facility -- but DCVax-L needs to have their own review and approval of Advent for commcercial production as part of the DCVax-L application review process.
It only benefits LP because Advent can produce cell-base therapies for any approved drug of theat type and she can make money on Advent.
News 
Market Data 
Discover 
